Glaxosmithkline: stock down as drug fails clinical trial

(CercleFinance.com) - GlaxoSmithKline shares are down over 1% on Thursday in London, following the group's announcement of the failure of a clinical trial in oncology.


In a statement released last night, GSK said it had followed a recommendation from its independent external committee to stop enrolling patients in a Phase II trial of feladilimab.

The trial was designed to assess the efficacy of pembrolizumab in combination with Merck's Keytruda, in the treatment of advanced or metastatic squamous cell cancer of the head and neck.

The company has also decided to terminate another phase II study evaluating the combination of both immunotherapy drugs with chemotherapy.



Copyright (c) 2021 CercleFinance.com. All rights reserved.